Sprout Pharmaceuticals Inc. is relaunching Addyi (flibanserin), the first-ever approved drug for low libido, or hypoactive sexual desire disorder (HSDD). Addyi’s sales success will depend on whether the modest benefits are considered adequate in relation to cost.